HelmyMGuirgisMD

Summary

• Dr. Helmy Guirgis is an oncologist based in Dana Point, CA, with a subspecialty in diagnosis and treatment of solid tumors. He completed his medical education at Creighton University School of Medicine, followed by an internship at the same institution, a residency in internal medicine at Mount Sinai Hospital Medical Center of Chicago, and fellowships in hematology and medical oncology at City of Hope National Medical Center and the University of California (Irvine). He is currently clinical Prof in medicine and oncology at UCI. Dr. Guirgis has published several articles focusing on the cost and effects of anticancer drugs, with topics covering advanced lung cancer and metastatic prostate cancer, some of which have been widely cited in the field.

SCITECH - Fresh Perspective on Costs of the Glucagon-Like-Peptide-1 Relative to
Patients fear hearing news of the dreadful cancer diagnosis. Cancer incidence has increased along the years. Lung cancer is the most fatal of all throughout the
Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-sm

The impact of PD-L1 on survival and value of the immune check point inhibitors i
The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objective